Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study of the Effects of a Combination of NeoRecormon, CellCept and Prednisone on Hematological Parameters and Cytogenesis in Patients With Low or Intermediate Risk Myelodysplastic Syndromes.¿

NCT00551291 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00551291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00551291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study of the Effects of a Combination of NeoRecormon, CellCept and Prednisone on Hematological Parameters and Cytogenesis in Patients With Low or Intermediate Risk Myelodysplastic Syndromes.¿
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
June 30, 2009
Enrollment
10 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes